This workshop will explore the need for early detection and identification of clinically important organisms, including the most prevalent ESKAPE pathogens, to provide earlier targeted therapy for the most critically compromised patients.

Join us as we discuss integrating the FDA-cleared T2Bacteria and T2Candida Panels in clinical practice and how it can impact patient management. Learn how early detection of the most serious bacterial and fungal pathogens in 3 to 5 hours direct from whole blood—and without waiting for blood culture—can improve on empiric therapy protocols and improve patient outcomes.